Adverse Events in Patients With Left Ventricular Noncompaction: Risk Stratification and Treatment Options

Aim. To study the clinical manifestations, incidence of life-threatening complications, and their possible mechanisms and outcomes of left ventricular non-compaction (LVNC) in adults.
Material and methods. This study included 125 adult patients with LVNC, 74 men (59.2%) and 51 women (40.8%) aged 46.4±15.1 years. Echocardiography (EchoCG) (n=125), Holter monitoring (n=125), cardiac magnetic resonance imaging (MRI) (n=60), and contrast-enhanced multislice computed tomography (MSCT) of the heart (n=90), and, if indicated, coronary angiography (CAG) (n=33) and myocardial scintigraphy (n=27) were performed. The diagnosis of LVNC was confirmed in 74 cases using two methods, and in 21 cases, using three imaging methods. DNA diagnostics was performed in most patients. For most patients, the level of anticardiac antibodies and the genome of cardiotropic viruses were determined in the blood. Mean left ventricular (LV) ejection fraction (EF) was 38.6±14.0%; LV end-diastolic volume (EDV) was 158.1±67.8 ml; LV end-diastolic dimension (EDD) was 6.1±0.9 cm; and left atrial (LA) volume was 97.1±38.1 ml. The mean follow-up period was 14 months [4.0; 41.0]; from 1 month to 10 years.
Results. Death rate was 14.4%; heart transplantation was performed in 5.6% of cases. Nonsustained ventricular tachycardia (VT) was detected in 45.6% of cases and sustained VT in 13.6%. The presence of VT was associated with poor R-wave progression in the precordial ECG leads, low QRS voltage, QRS duration >105 ms, NYHA chronic heart failure functional class (CHF FC) ≥2-3, LV EF <40%; LV EDD >6.1 cm, the presence of myocarditis, and higher death rate. Cardioverter defibrillators, including cardiac resynchronization therapy defibrillators (CRTD), were implanted in 38 patients. Appropriate defibrillator shocks were associated with frequent premature ventricular contractions (PVCs). The incidence of thrombosis and embolism was 22.4%. Their predictors included CHF FC ≥2-3, RV anteroposterior dimension >3.1 cm, LA volume >98 ml, E/A >1.65, LV EDD >6.3 cm, LV EDV >153 ml, LV EF <35%, and myocardial necrosis of unknown origin (in patients without coronary atherosclerosis). The incidence of myocardial necrosis in LVNC was 16.0%. The mechanisms identified, in addition to coronary atherosclerosis, were embolism in unchanged coronary arteries, secondary myocarditis, and the presence of genetically determined thrombophilia.
Conclusion. LVNC is associated with a high risk of life-threatening conditions, such as ventricular arrhythmias, thrombosis and embolism, and myocardial necrosis, that are typical complications of LVNC in adults. Reassessing the predictors for the risk of thromboembolic and arrhythmic events, specifying the indications for implantable cardioverter defibrillator and anticoagulants, and actively identifying and treating concomitant myocarditis are essential.

1. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation. 1990;82(2):507–13. DOI: 10.1161/01.CIR.82.2.507

2. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86(6):666–71. PMID: 11711464

3. Stöllberger C, Finsterer J. Left ventricular hypertrabeculation/noncompaction. Journal of the American Society of Echocardiography. 2004;17(1):91–100. DOI: 10.1016/S0894-7317(03)00514-5

4. Stöllberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. The American Journal of Cardiology. 2002;90(8):899–902. DOI: 10.1016/S00029149(02)02723-6

5. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. Journal of the American College of Cardiology. 2005;46(1):101–5. DOI: 10.1016/j.jacc.2005.03.045

6. Jacquier A, Thuny F, Jop B, Giorgi R, Cohen F, Gaubert JY et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. European Heart Journal. 2010;31(9):1098–104. DOI: 10.1093/eurheartj/ ehp595

7. Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Longterm follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. Journal of the American College of Cardiology. 2000;36(2):493–500. PMID: 10933363

8. Lofiego C, Biagini E, Pasquale F, Ferlito M, Rocchi G, Perugini E et al. Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart. 2007;93(1):65–71. DOI: 10.1136/ hrt.2006.088229

9. Blagova O.V., Nedostup A.V., Sedov V.P., Gagarina N.V., Kogan Е.A., Sulimov V.A. et al. Noncompaction myocardium as a primary phenomenon or consequence of myocardial dysfunction: clinical masks of the syndrome. Kardiologiia. 2012;52(11):17–26.

10. Pavlenko E.V., Blagova O.V., Varionchik N.V., Nedostup A.V., Sedov V.P., Polyak M.E. et al. Register of adult patients with noncompact left ventricular myocardium: classification of clinical forms and a prospective assessment of progression. Russian Journal of Cardiology. 2019;24(2):12–25. DOI: 10.15829/1560-4071-2019-2-12-25

11. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI: 10.1161/CIRCULATIONAHA.106.174287

12. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal. 2007;29(2):270–6. DOI: 10.1093/eur-heartj/ehm342

13. van Waning JI, Caliskan K, Hoedemaekers YM, van SpaendonckZwarts KY, Baas AF, Boekholdt SM et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. Journal of the American College of Cardiology. 2018;71(7):711–22. DOI: 10.1016/j.jacc.2017.12.019

14. Stämpfli SF, Erhart L, Hagenbuch N, Stähli BE, Gruner C, Greutmann M et al. Prognostic power of NT-proBNP in left ventricular non-compaction cardiomyopathy. International Journal of Cardiology. 2017;236:321–7. DOI: 10.1016/j.ijcard.2017.02.064

15. Arenas IA, Mihos CG, DeFaria Yeh D, Yucel E, Elmahdy HM, Santana O. Echocardiographic and clinical markers of left ventricular ejection fraction and moderate or greater systolic dysfunction in left ventricular noncompaction cardiomyopathy. Echocardiography. 2018;35(7):941–8. DOI: 10.1111/echo.13873

16. Oechslin E, Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? European Heart Journal. 2011;32(12):1446–56. DOI: 10.1093/eurheartj/ehq508

17. Casas G, Limeres J, Oristrell G, Gutierrez-Garcia L, Andreini D, Borregan M et al. Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction. Journal of the American College of Cardiology. 2021;78(7):643–62. DOI: 10.1016/j.jacc.2021.06.016

18. Ramchand J, Podugu P, Obuchowski N, Harb SC, Chetrit M, Milinovich A et al. Novel Approach to Risk Stratification in Left Ventricular Non‐Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach. Journal of the American Heart Association. 2021;10(8):e019209. DOI: 10.1161/JAHA.120.019209

19. Zhou H, Lin X, Fang L, Zhu W, Zhao X, Ding H et al. Prolonged QTc indicates the clinical severity and poor prognosis in patients with isolated left ventricular non-compaction. The International Journal of Cardiovascular Imaging. 2017;33(12):2013–20. DOI: 10.1007/s10554-017-1209-9

20. Ekizler FA, Cay S, Ulvan N, Tekin Tak B, Cetin EHO, Kafes H et al. Importance of lead aVR on predicting adverse cardiac events in patients with noncompaction cardiomyopathy. Annals of Noninvasive Electrocardiology. 2020;25(3):e12719. DOI: 10.1111/anec.12719

21. Ichida F. Left ventricular noncompaction − Risk stratification and genetic consideration. Journal of Cardiology. 2020;75(1):1–9. DOI: 10.1016/j.jjcc.2019.09.011

22. Stöllberger C, Wegner C, Finsterer J. CHADS2- and CHA2DS2VASc Scores and Embolic Risk in Left Ventricular Hypertrabeculation/Noncompaction. Journal of Stroke and Cerebrovascular Diseases. 2013;22(6):709–12. DOI: 10.1016/j.jstrokecerebrovasdis.2011.10.014

23. Kido K, Guglin M. Anticoagulation Therapy in Specific Cardiomyopathies: Isolated Left Ventricular Noncompaction and Peripartum Cardiomyopathy. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(1):31–6. DOI: 10.1177/1074248418783745

24. Chimenti C, Lavalle C, Magnocavallo M, Alfarano M, Mariani MV, Bernardini F et al. A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. ESC Heart Failure. 2022;9(1):241–50. DOI: 10.1002/ehf2.13694

25. Saguner AM, Ganahl S, Baldinger SH, Kraus A, Medeiros-Domingo A, Nordbeck S et al. Usefulness of Electrocardiographic Parameters for Risk Prediction in Arrhythmogenic Right Ventricular Dysplasia. The American Journal of Cardiology. 2014;113(10):1728–34. DOI: 10.1016/j.amjcard.2014.02.031

26. Blagova O.V., Lutokhina Yu.A., Varionchik N.V., Solovyeva E.A., Bukaeva A.A., Shestak A.G. et al. Risk stratification of sudden death and selection criteria for the implantation of defibrillators in patients with cardiomyopathies (dilated, arrhythmogenic right ventricular, noncompact myocardium). Clinical and Experimental Surgery. Petrovsky journal. 2018;6(3):34–49. DOI: 10.24411/2308-1198-2018-13004

27. Sigvardsen PE, Fuchs A, Kühl JT, Afzal S, Køber L, Nordestgaard BG et al. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study. European Heart Journal - Cardiovascular Imaging. 2021;22(1):67–74. DOI: 10.1093/ehjci/jeaa110

28. Blagova O.V., Pavlenko E.V., Varionchik N.V., Nedostup A.V., Sedov V.P., Kogan Е.A. et al. Myocarditis as a legitimate phenomenon in non-compaction myocardium: diagnostics, management and influence on outcomes. Russian Journal of Cardiology. 2018;23(2):44–52. DOI: 10.15829/1560-4071-2018-2-44-52

29. Jefferies JL. Left Ventricular Noncompaction Cardiomyopathy: New Clues in a Not So New Disease? Journal of the American Heart Association. 2021;10(2):e018815. DOI: 10.1161/JAHA.120.018815

30. Vaidya VR, Lyle M, Miranda WR, Farwati M, Isath A, Patlolla SH et al. Long‐Term Survival of Patients With Left Ventricular Noncompaction. Journal of the American Heart Association. 2021;10(2):e015563. DOI: 10.1161/JAHA.119.015563

31. Feng Y, Ning L, Zhang J, Wang H, Zhang H, Zhang R et al. Prognosis and subtype analysis of left ventricular noncompaction in adults: A retrospective multicenter study. Clinical Cardiology. 2023;46(4):390–6. DOI: 10.1002/clc.23991

32. Cuevas J, Ptaszynski R, Cigarrán H, Calvo J, Martín M. Left ventricular noncompaction cardiomyopathy: Recent advances. Kardiologia Polska. 2022;80(5):529–39. DOI: 10.33963/KP.a2022.0089